Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs

Go back to Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs

Incyte (INCY) PT Raised to $140 at Jefferies on 4Q Report, Jakafi Metrics

February 15, 2017 8:10 AM EST

Jefferies analyst Brian Abrahams reiterates Buy rating and raises price target on Incyte Corp. (NASDAQ: INCY) to $140 (from $136) as the company delivered in-line Jakafi sales figures, while offering positive guidance.

Abrahams comments, "Solid, unsurprising Valentine's Day 4Q report, with good Jakafi metrics and... More

RBC Capital Reiterates Outperform Rating on Incyte (INCY) Following 4Q Results

February 14, 2017 9:37 AM EST

RBC Capital Markets analyst Simos Simeonidis reiterates Outperform rating on Incyte Corporation (NASDAQ: INCY) suggesting Jakafi continues to grow, despite the company reporting 2016 fourth quarter revenues below consensus.

Simeonidis comments, INCY reported slightly below consensus Jakafi/total revenue numbers, despite decent growth five years... More

Incyte (INCY) Misses Q4 EPS by 8c

February 14, 2017 7:11 AM EST

Incyte (NASDAQ: INCY) reported Q4 EPS of $0.05, $0.08 worse than the analyst estimate of $0.13. Revenue for the quarter came in at $326 million versus the consensus estimate of $324.42 million.

For earnings history and earnings-related data on Incyte (INCY) click here.

... More